Drugs / 177Lu-CTR-FAPI
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07229768 | Oct 2025 → Nov 2026 expected | malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT07587996 | Nov 2024 → Mar 2026 | metastatic malignant neoplasm | Lanzhou University Second Hospital | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07438847 | Jan → Dec 2026 expected | thyroid cancer | SHAOYAN LIU | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07014254 | Jun 2025 → Apr 2028 expected | colorectal cancer, gastric adenocarcinoma, neuroendocrine neoplasm, pancreatic ductal adenocarcinoma | Xijing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-CTR-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07014254 ↗ |
| Action | Inhibit | “fibroblast activation protein inhibitor” NCT07438847 ↗ |
| Modality | Other / unclassified | “The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi)” NCT07014254 ↗ |
| Route | Intravenous | “given slowly by intravenous infusion over 20-30 minutes” NCT07014254 ↗ |